SCHEMBL6476602

SCHEMBL6476602

Cc1cc(Cc2ccc(F)cc2)c(=O)n2nc(C(=O)O)oc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR1 P21462 5/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CNR2 P34972 2/20 0.38
GPR55 Q9Y2T6 2/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
FPR2 P25090 2/20 0.36
MAPK14 Q16539 1/20 0.36
CNR1 P21554 1/20 0.35
P2RY14 Q15391 1/20 0.35
RET P07949 1/20 0.34
MAPT P10636 1/20 0.34
KDR P35968 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
PTGER1 P34995 1/20 0.34
PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475923 0.85 MAPT (0.46) MEN1KMT2AMAPTALDH1A1GAA
SCHEMBL6484092 0.78 MEN1 (0.38) FPR1MEN1KMT2ACNR2GPR55
SCHEMBL6485436 0.77 CNR2 (0.40) FPR1MEN1KMT2ACNR2GPR55
SCHEMBL6483747 0.77 NR1H4 (0.44) MEN1KMT2AMAPTALDH1A1
SCHEMBL6484773 0.75 MEN1 (0.41) FPR1MEN1KMT2ACNR2GPR55
SCHEMBL6819023 0.70 MMP13 (0.38) MEN1KMT2AMAPTALDH1A1
SCHEMBL6484094 0.69 LMNA (0.42) FPR1MEN1KMT2ACNR2GPR55
SCHEMBL6289352 0.68 PLA2G7 (0.38) MEN1KMT2ACNR2GPR55MAPK14
SCHEMBL6818481 0.68 ALDH1A1 (0.45) MEN1KMT2ACNR2MAPTALDH1A1
SCHEMBL6476432 0.68 ALDH1A1 (0.47) MEN1KMT2ACNR2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-6897223-B2 Pyridine fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-05-24 US disclosed
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed
WO-2004014908-A1 HETEROBICYLCIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039012-A1 Pyridine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 FPR1 175/4885MEN1 3457/4885KMT2A 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.